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Does comorbidity explain trends in prescribing of newer
antihypertensive agents?
Jacoba P. Grevinga, Petra Deniga, Willem Jan van der Veenb,
Frank W. Beltmanb, Miriam C. J. M. Sturkenboomc,d, Dick de Zeeuwa and
Flora M. Haaijer-Ruskampa
Objective Concerns exist about heavily prescribing of new
drugs when the evidence on hard outcomes is still limited.
This has been the case for the newer classes of
antihypertensives, especially in hypertensive patients
without additional comorbidity. The association between
comorbidity and trends in prescribing of angiotensin-
converting enzyme inhibitors (ACE-I) and angiotensin II
receptor blockers (ARBs) was examined for the period
1996–2000.
Design and methods Data were obtained from the
Integrated Primary Care Information database, which
contains medical records from more than 100 general
practitioners in the Netherlands. Prevalent drug use in
hypertensive patients was determined per calendar year.
As initial treatment, the first antihypertensive drug
prescribed within 1 year after diagnosis of hypertension
was considered. Logistic regression was used to estimate
the likelihood of receiving either ACE-I or ARBs.
Results The overall prevalent ACE-I use remained stable
(31%), but it increased from 33 to 41% in hypertensive
patients with diabetes, heart failure, proteinuria and/or
renal insufficiency. ARB use increased significantly from 2
to 12%; this trend did not differ between patients with or
without specific comorbidities. Initial ACE-I use slightly
decreased (from 29% to 24%), whereas initial ARB use
significantly increased (from 4% to 12%). ACE-I were more
likely to be the first treatment in patients with diabetes
[odds ratio (OR) 3.9; 95% confidence interval (CI) 3.2–
4.9] or hypercholesterolemia (OR 1.4; 95% CI 1.1–1.8).
ARBs were more likely to be the initial treatment in
patients with asthma/chronic obstructive pulmonary
disease (OR 1.6; 1.2–2.3), diabetes (OR 2.1; 1.5–2.9) or
hypercholesterolemia (OR 1.7; 1.2–2.4).
Conclusions The increased use of ACE-I is mostly
restricted to hypertensive patients with comorbidities for
which their use has been recommended. Trends in
prescribing of ARBs are not related to relevant
comorbidities. J Hypertens 22:2209–2215 & 2004
Lippincott Williams & Wilkins.
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Introduction
There is an ongoing debate regarding which drug class
should be preferred for treating hypertension [1,2]. Over
the years, most national and international guidelines have
recommended diuretics and -blockers as first-choice
agents for the treatment of hypertension without comor-
bidity because benefits on hard outcomes have been
demonstrated for these drugs [3–5]. One of the debated
issues is the role that angiotensin-converting enzyme
inhibitors (ACE-I) and, more recently, angiotensin II
receptor blockers (ARBs) have in treating uncomplicated
hypertension. The first studies showing benefits in terms
of cardiovascular morbidity and mortality in hypertension
patients were published in 1999 for ACE-I [6–8], and in
2002 for ARBs [9] (Fig. 1). However, during the preced-
ing years in which the cardiovascular disease outcomes of
these newer antihypertensive drugs were largely un-
known, large shifts were observed in the use of these
drugs in hypertensive patients [10–15].
However, evidence that ACE-I are effective in reducing
morbidity and mortality in patients with heart failure or
diabetes mellitus was available several years earlier [16–
18]. Based on this evidence, ACE-I have been recom-
mended in the Dutch hypertension guidelines since
1997 as first-choice agents for hypertensive patients who
also have heart failure or diabetes mellitus, especially in
the presence of proteinuria [3,4]. ARBs, which were
introduced in the Netherlands in 1995, were first men-
tioned in a Dutch hypertension guideline in 2000, and
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are recommended as alternative for ACE-I when these
drugs are not well tolerated [4]. It might be expected
that increases in the use of ACE-I and ARBs have been
the largest in these specific patient groups for which
they have been recommended. In a survey conducted in
the USA in 1997, primary care physicians reported that
they increased the use of ACE-I as initial therapy for
hypertensive patients with heart failure or diabetes [19].
Cross-sectional analyses of prescription data showed that
ACE-I were more likely to be prescribed in hyper-
tensive patients with certain comorbidities, such as
diabetes, hypercholesterolemia, heart failure, history of
myocardial infarction or angina pectoris [11–13]. There
are also some descriptive studies indicating that in-
creased ACE-I use is influenced by the presence of
comorbidities, such as diabetes [20,21]. However, these
studies do not rigorously analyse the effect of comorbid-
ity on changes in ACE-I and ARB prescribing over time.
Given the difference in available evidence and recom-
mendations on hard outcomes, it is important to analyse
trends in the prescribing of ARBs separate from ACE-I.
The aim of this study was to examine the trends in
prevalent and initial use of ACE-I and ARBs in com-
parison with other drug classes for the treatment of
hypertension from 1996 to 2000, and to clarify the role
of comorbidity in explaining these trends. The findings
will shed new light regarding the extent that physicians




In this study, data from the Integrated Primary Care
Information (IPCI) database from the Erasmus Medical
Center were used. This is a longitudinal general prac-
tice research database containing the complete electro-
nic medical records from more than 100 Dutch general
practitioners (GPs) participating on a voluntary basis,
receiving a yearly financial reward. In the Netherlands,
patients are registered to a single GP who has a
gatekeeper role in coordinating their medical care. GPs
contributing to the IPCI database are not permitted to
use paper-based records in addition to their electronic
medical records. They all prescribe electronically using
a uniform coding system, and use the International
Classification for Primary Care (ICPC) for diagnosis
coding [22]. Information on drug prescriptions com-
prises brand name, quantity, strength, indication, pre-
scribed daily dose and the anatomical therapeutical
chemical classification (ATC) code [23]. The computer
records further contain information on patient demo-
graphics, referrals, and textual medical data entered by
the GP. Thus, the records can be considered to contain
all drug prescriptions, and all clinical information con-
sidered relevant by the GPs for providing adequate care
for their patients. The database complies with Eur-
opean Union guidelines on the use of medical data for
medical research, and has been proven valid using
different reference methods for pharmaco-epidemio-
logical research [24].
Study period and population
The 5-year study period started on 1 January 1996 and
ended on 31 December 2000. The source population
comprised all individuals aged more than 18 years who
had at least 6 months registration with their GP in the
IPCI database during the study period. All patients
with either a ICPC-coded diagnosis of hypertension or
hypertension in the patient diary as free text were
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Fig. 1
Relevant trial results and Dutch guideline recommendations regarding ACE inhibitors and angiotensin II receptor blockers before, during and after
the study period. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; DIU, diuretic; BB, -blocker; CCB, calcium
channel blocker.
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selected. This latter group was manually evaluated to
include only those patients where hypertension was
mentioned as their diagnosis.
For hypertensive patients, all prescriptions written after
diagnoses of hypertension for any of the five main
antihypertensive drug classes were selected. This in-
cludes diuretics, -blockers, calcium channel blockers,
ACE-I and ARBs. Furthermore, for each patient, the
presence of specific comorbidities using the ICPC-
codes and free text or, when possible, the ATC-code
for indication-specific drugs were identified. The fol-
lowing comorbidities that might influence the choice of
hypertension treatment were included: angina pectoris,
ankle oedema, arrhythmia, asthma and/or chronic ob-
structive pulmonary disease (COPD), diabetes mellitus,
gout, heart failure, hypercholesterolemia, myocardial
infarction, proteinuria and/or renal insufficiency, and
stroke. Data were also collected on referrals to an
internist or cardiologist because patients with comor-
bidities are more likely to be referred to a specialist,
and specialists have been found to prescribe more
ACE-I than GPs [25].
Estimation of antihypertensive drug use
To be able to look at trends in use of antihypertensives
in independent groups of patients, 20% of all patients
registered in the IPCI database in each calendar year
were randomly sampled. For each calendar year, pre-
valent antihypertensive drug use was estimated on the
first Wednesday in October. A hypertensive patient was
defined as prevalent user of a certain class of antihyper-
tensive drugs based on the last prescription in the
6 months before the index date. Initial drug use was
assessed for all newly diagnosed hypertensive patients
as the first antihypertensive drug prescribed within
1 year after the diagnosis, excluding patients who used
any antihypertensive drugs in the 6 months before
initiation of hypertension therapy.
Statistical analysis
The outcome variables studied were prevalent and
initial use of ACE-I and ARBs, including monotherapy
as well as combination therapy containing an ACE-I or
ARB. The likelihood of receiving ACE-I or ARB was
estimated through logistic regression analysis. As a
reference category, users of classic antihypertensives
(i.e. diuretics, -blockers and calcium channel blockers)
were chosen. In all models, an adjustment was made
for sex and age (categorized as 18–50, 50–59, 60–69,
70–79, 80 years and above), because substantial sex and
age differences have been found in antihypertensive
drug choice [11]. First, the effect of comorbidity or
referrals to a cardiologist or internist were explored in
separate univariate models, that include also year, sex
and age. To verify whether a specific comorbidity
explained the time trend in the likelihood of receiving
an ACE-I or ARB, an interaction term consisting of the
comorbidity in question and calendar year was added in
each univariate regression model. If this interaction
term was significant and the stratified analysis showed a
trend over the years than this comorbidity would partly
explain trends in prescribing of newer antihyperten-
sives. Next, all significant factors were included in the
final multivariate logistic regression model using a
stepwise procedure.
Results
The number of individuals aged more than 18 years
who were registered for at least 6 months in the IPCI
database increased from 95 974 in 1996 to 160 397 in
2000. In our random samples in each calendar year, a
total of 115 344 patients were selected and 10 706
patients with a diagnosis of hypertension were identi-
fied. Hypertensive patients had a mean  SD age of
63  14 years, and 61% were women (ranging from 54%
in the lowest age group to 77% in the highest age
group). Of these patients, 54% had hypertension with
at least one comorbidity; 1774 (17%) had diabetes, 1835
(17%) had hypercholesterolemia and 553 (5.2%) had
heart failure. The average number of comorbidities
increased from 0.4 in the lowest age group to 1.4 in the
highest age group.
Prevalent antihypertensive drug use
In the 10 706 patients with a hypertension diagnosis,
7550 hypertensive patients who were prevalent users of
any antihypertensive drug were identified. From 1996
to 2000, prevalent antihypertensive drug use varied
from 68 to 73% in all hypertensive patients. Prevalent
use of the five antihypertensive drug classes differed
between various patient subgroups (e.g. sex, age, refer-
rals and comorbidities) (Table 1). Time trends showed
that there was a significant increase in prevalent use of
-blockers (from 38 to 43%) and ARBs (from 2 to 11%),
whereas prevalent use of calcium channel blockers
somewhat decreased (from 22 to 21%), and prevalent
use of diuretics (41%) and ACE-I (31%) remained
stable over the years. Overall, the average number of
antihypertensives prescribed per patient increased from
1.4 to 1.5.
Prevalent ACE-I use
In hypertensive patients without any comorbidity,
approximately 29% were treated with an ACE-I. In
hypertensive patients who also suffered from diabetes,
heart failure, proteinuria and/or renal insufficiency, the
prevalent use of ACE-I increased from 32.9 to 40.8%
(Fig. 2). The univariate analysis confirmed that dia-
betes, heart failure and proteinuria and/or renal insuffi-
ciency were the strongest predictors of ACE-I use
[odds ratios (OR) ¼ 1.7, 1.4 and 1.4, respectively].
Other significant comorbidities were hypercholesterole-
mia (OR ¼ 1.2), angina pectoris (OR ¼ 0.8) and ankle
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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oedema (OR ¼ 0.8). Multivariate logistic regression
showed that ACE-I were significantly more likely to be
prescribed than classic antihypertensives to patients
with diabetes, heart failure, hypercholesterolemia or
patients referred to an internist (Table 2). Patients with
angina pectoris or ankle oedema were less likely to be
prescribed ACE-I. No significant interactions were
detected between individual comorbidities and trends
in prevalent use of ACE-I, although the interaction
between diabetes and trends in prevalent ACE-I use
was of borderline significance (test for interaction,
P ¼ 0.058). In 2000, hypertensive patients with dia-
betes were more likely to be prescribed ACE-I than in
1996 [OR ¼ 1.8; 95% confidence interval (CI) 1.2–2.8].
When combining patients with at least one comorbidity
for which ACE-I are recommended (i.e. diabetes, heart
failure, proteinuria and/or renal insufficiency), a signifi-
cant interaction between these comorbidities and
trends in prevalent ACE-I use was found (test for
interaction, P ¼ 0.030). In 2000, hypertensive patients
with diabetes, heart failure, proteinuria and/or renal
insufficiency were more likely to be prescribed ACE-I
than in 1996 (OR ¼ 1.7; 95% CI 1.1–2.6).
Initial ACE-I use
From 1996 to 2000, 3973 newly treated hypertensive
patients were identified. More than one-quarter of
these patients were younger than 50 years of age and
40% had at least one comorbidity. The percentage of
initial ACE-I use in newly treated hypertensive pa-
tients decreased from 28.7 to 23.5%. In hypertensive
patients who also had diabetes, heart failure, protein-
uria and/or renal insufficiency, the percentage starting
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 1 Prevalent use of diuretics, -blockers, calcium channel blockers, angiotensin-converting
enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARBs) in 7550 treated hypertensive
patients
n (%) % Diuretics % -blockers % CCB % ACE-I % ARBs
Period of time
1996 1044 (14) 41.0 38.2 22.1 31.8 2.1
1997 1499 (20) 42.3 41.3 20.1 30.8 3.8
1998 1786 (24) 41.6 41.7 21.1 31.2 7.4
1999 1903 (25) 39.9 41.3 18.5 30.4 10.8
2000 1318 (17) 41.3 42.9 20.6 31.6 11.5
Sex
Male 2776 (37) 31.7 41.0 24.3 36.7 8.2
Female 4774 (63) 46.7 41.4 18.0 27.8 7.1
Age
, 50 years 929 (12) 27.2 46.3 14.7 32.7 8.1
50–59 years 1625 (22) 35.1 48.4 18.3 32.0 8.3
60–69 years 1920 (25) 39.5 42.8 21.5 31.9 7.2
70–79 years 2083 (28) 46.3 37.1 22.9 29.8 7.9
80 years and above 993 (13) 56.4 30.5 21.1 29.2 5.5
Referral
Internist 1784 (20) 40.8 36.2 26.0 34.3 9.1
Cardiologist 1532 (24) 37.2 42.6 28.8 31.3 9.7
Comorbidity
No comorbidity 3306 (44) 40.7 46.0 15.4 28.5 7.4
Angina pectoris 878 (12) 37.4 47.3 32.5 26.4 7.2
Ankle oedema 691 (9) 57.3 30.8 22.9 25.6 7.5
Arrhythmia 691 (9) 41.1 38.8 23.7 31.1 9.4
Asthma/COPD 669 (9) 46.5 22.6 26.0 33.2 11.8
Diabetes 1308 (17) 44.0 33.3 22.6 39.8 7.0
Gout 389 (5) 40.1 41.4 25.4 37.3 6.7
Heart failure 454 (6) 62.3 21.1 17.8 36.1 8.6
Hypercholesterolemia 1344 (18) 35.0 43.1 26.9 34.3 8.8
Myocardial infarction 482 (6) 36.1 51.0 32.2 31.7 6.0
Proteinuria/renal insufficiency 185 (2) 44.3 31.9 28.6 37.3 11.4
Stroke 560 (7) 40.5 36.1 28.0 31.1 8.9








1996 1997 1998 1999 2000
ACE-I 0 (n  943)
ACE-I 1 (n  659)
ACE-I 2 (n  744)
ARB 0 (n  246)
ARB 1 (n  129)
ARB 2 (n  193)
Fig. 2
Prevalent use of angiotensin-converting enzyme inhibitors (ACE-I) and
angiotensin II receptor blockers (ARB) in 7550 treated hypertensive
patients grouped by comorbidity (group 0 ¼ no comorbidity; group
1 ¼ diabetes, heart failure, proteinuria and/or renal insufficiency; group
2 ¼ other comorbidity).
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on an ACE-I was much higher, and increased from 42.7
to 51.8% in 1998 but decreased again to 44.4% in 2000
(Fig. 3). Multivariate logistic regression showed that
ACE-I were more likely to be the initial therapy com-
pared with classic antihypertensives for patients with
diabetes or hypercholesterolemia (Table 2). No signifi-
cant interaction between comorbidity and trends in
initial use of ACE-I was found. However, initial ACE-I
use and year tended to be related among hypertensive
patients with diabetes (test for interaction, P ¼ 0.057),
and among hypertensive patients with at least one of
the comorbidities diabetes, heart failure, proteinuria
and/or renal insufficiency (test for interaction, P ¼
0.060).
Prevalent ARB use
Trends in prevalent use of ARB did not differ between
patients with or without comorbidities (Fig. 2). In the
univariate analysis, asthma and/or COPD, and protei-
nuria and/or renal insufficiency were the strongest
predictors of ARB use (OR ¼ 1.8 and 1.8, respectively).
Multivariate analysis showed that prevalent ARB use
was more likely in patients with asthma and/or COPD
and patients referred to a cardiologist or internist
(Table 2). Patients with a history of myocardial infarc-
tion were less likely to be prescribed an ARB. No
significant interactions were detected between indivi-
dual comorbidities and trends in prevalent use of
ARBs.
Initial ARB use
Initial ARB use increased significantly from 4.0 to
12.2%, mostly at the expense of initial ACE-I use (28.7
to 23.5%) and calcium channel blocker use (11.6 to
6.2%). Increases in initial ARB use did not differ
between patients with or without comorbidities (Fig.
3). ARBs were more likely to be initially prescribed to
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 2 Patient characteristics independently associated with prevalent use or initial use
of angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers
(ARBs) in treated hypertensive patients
ACE-I; OR (95% CI) ARB; OR (95% CI)
Characteristics Prevalent use Initial use Prevalent use Initial use
Year
1996 Reference Reference Reference
1997 – 0.9 (0.7–1.2) 1.7 (1.1–2.9) 1.9 (1.1–3.2)
1998 – 0.8 (0.6–1.0) 3.8 (2.4–6.0) 2.3 (1.4–3.8)
1999 – 0.7 (0.5–0.9) 5.5 (3.5–8.7) 2.9 (1.8–4.6)
2000 – 0.8 (0.6–1.0) 6.0 (3.8–9.5) 3.1 (1.9–5.0)
Age
, 50 years Reference
50–59 years – – 1.0 (0.7–1.3) –
60–69 years – – 0.9 (0.6–1.2) –
70–79 years – – 0.9 (0.7–1.2) –
80 years and above – – 0.6 (0.4–0.9) –
Sex
Female 0.6 (0.6–0.7) 0.6 (0.6–0.8) 0.8 (0.6–0.9) 0.8 (0.6–1.0)
Referral
Internist 1.2 (1.1–1.4) 1.3 (1.1–1.6) 1.3 (1.1–1.6) –
Cardiologists – 1.4 (1.1–1.7) 1.6 (1.2–2.0) –
Comorbidity
Angina pectoris 0.7 (0.6–0.8) – 0.7 (0.5–1.0) –
Ankle oedema 0.7 (0.6–0.9) – – 0.4 (0.2–0.8)
Asthma/COPD – – 1.8 (1.4–2.3) 1.6 (1.2–2.3)
Diabetes 1.6 (1.4–1.8) 3.9 (3.2–4.9) – 2.1 (1.5–2.9)
Heart Failure 1.4 (1.1–1.7) – – –
Hypercholesterolemia 1.2 (1.1–1.4) 1.4 (1.1–1.8) – 1.7 (1.2–2.4)
Myocardial Infarction – – 0.6 (0.4–1.0) –









1996 1997 1998 1999 2000
ACE-I 0 (n  468)
ACE-I 1 (n  269)
ACE-I 2 (n  235)
ARB 0 (n  206)
ARB 1 (n  59)
ARB 2 (n  115)
Fig. 3
Initial use of angiotensin-converting enzyme inhibitors (ACE-I) and
angiotensin II receptor blockers (ARB) in 3973 newly treated
hypertensive patients grouped by comorbidity (group 0 ¼ no
comorbidity; group 1 ¼ diabetes, heart failure, proteinuria and/or renal
insufficiency; group 2 ¼ other comorbidity).
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patients with diabetes, hypercholesterolemia, asthma
and/or COPD than classic antihypertensives (Table 2).
Patients with ankle oedema were less likely to be
prescribed an ARB as initial therapy. We found no
significant interaction between comorbidity and trends
in initial use of ARBs.
Discussion
This study showed significant trends in the choice of
antihypertensive treatment in the period from 1996 to
2000, which correspond with the general trends in
antihypertensive prescriptions in the Netherlands
[26,27]. There is an increased use of antihypertensive
drug treatment in general, and specific increases in the
use of -blockers and ARBs. Although the overall use
of ACE-I had stabilized, we observed an increased use
of ACE-I in patients for which such drugs were
recommended (i.e. hypertensive patients with diabetes,
heart failure, proteinuria and/or renal insufficiency).
ARB use increased significantly in all hypertensive
patients, but this trend did not differ between patients
with or without specific comorbidities. Initial treatment
with an ARB increased from 4% in 1996 to 12% in
2000, mostly at the expense of ACE-I and calcium
channel blockers. In all years, approximately 30% of
the newly treated hypertensive patients without any
relevant comorbidity received an ACE-I or an ARB as
initial treatment. These findings confirm that these
antihypertensive drugs are used whereas long-term
benefits are still uncertain and sufficient evidence-
based alternatives are available. On the other hand, the
differences in prescribing patterns between ACE-I and
ARBs suggest that increases in use of new drugs shortly
after their introduction are largely not specific but, in
later years, are confined to patients for whom this is
more evidence-based.
Previous studies demonstrated that, between 1980 and
1998, the use of diuretics and -blockers declined
whereas the use of ACE-I (sometimes including ARBs)
increased for treatment of hypertension [10–15]. Our
study shows that this pattern is more complicated when
differentiating for ACE-I and ARBs, and also for
specific subgroups of patients. The relevance of these
subgroups was already supported by studies indicating
that ACE-I were more commonly prescribed to hyper-
tensive patients with diabetes, hypercholesterolemia,
heart failure, history of myocardial infarction or angina
pectoris [11–13,20,21]. Looking at the influence of
comorbidity during our whole study period, we could
confirm some of these associations. Diabetes was the
most important predictor, especially for initial ACE-I
and ARB use. Hypertensive patients with diabetes
were almost four-fold more likely to receive an initial
treatment with ACE-I, and two-fold more likely to
receive initial ARB treatment. ACE-I use was also
higher in patients with heart failure, proteinuria and/or
renal insufficiency, but this association diminished after
adjusting for specialists’ influences. Previous studies
that did not correct for this influence may therefore
have overestimated the actual influence of some of
these comorbidities. By contrast to previous studies, we
found a negative association with ACE-I use for pa-
tients with a history of myocardial infarction or angina
pectoris. This is not surprising because we compared
ACE-I users with all users of classic antihypertensives,
including -blockers, whereas other studies used only
diuretics as reference category [11–13]. The positive
association between patients with hypercholesterolemia
and the use of ACE-I and ARB is consistent with
previous findings [11]. There are no specific recommen-
dations for the hypertension treatment of this group of
patients, and there is no clear reason for especially
prescribing ACE-I in patients with this additional risk
factor. One possible explanation might be that thiazide
diuretics are less favoured for these patients based on
reports that they could induce small increases in
cholesterol levels [28]. Finally, where other studies
already reported that hypertensive patients with asthma
and/or COPD were less likely to receive -blockers
[11,12], it became clear from our study that ARBs are
used more often as an (initial) antihypertensive treat-
ment for these patients. Although none of the guide-
lines recommend ARBs for these patients, physicians
may be more inclined to use these drugs to avoid
bronchospasm caused by -blockers [29].
An important strength of our study is that we used data
from a large, longitudinal database comprising informa-
tion about diagnoses and prescriptions on a patient
level. This allowed us to look at the influence of
various patient characteristics on both initial and pre-
valent use of ACE-I and ARBs. In addition, we
adjusted for referrals to disentangle the effect of
specialists’ prescribing from the effect of comorbidity
on prescribing patterns in general practice. This is
relevant because we observed that patients who were
referred to an internist or cardiologist were more likely
to be prescribed ACE-I and ARBs, and medication
initiated by specialists is frequently continued by GPs
[30].
A limitation of this study is the lack of a specific
diagnosis for each medication. As with many cardio-
vascular drugs, the agents followed in this study may
be indicated for the treatment of various diseases. From
the GP records, it was not always possible to ascertain
the cardiovascular diagnosis for which a particular drug
was being used, and one drug may be prescribed to
simultaneously treat more than one cardiovascular dis-
ease in an individual patient. However, each of the
patients included in this study had a diagnosis of
hypertension registered in their GP record. Given this,
we can assume that the cardiovascular medications
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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included in this study were either prescribed directly
for hypertension or to treat a combination of hyper-
tension and some coexisting conditions.
In conclusion, the use of ACE-I and ARBs is partly
related to several comorbidities, only some of which are
clearly evidence-based. Although, ACE-I use was simi-
lar in the different patient groups in 1996, it increased
by the year 2000 in hypertensive patients with comor-
bidities for which its use has been recommended. By
contrast, trends in prescribing of ARBs are not in
agreement with evidence-based guidelines at that time.
ARB use significantly increased immediately after its
introduction in 1995 in hypertensive patients with and
without comorbidities. Apparently, these newer antihy-
pertensive agents are considered as a first-choice drug
in a non-selective group of hypertensive patients. The
steep rise in ARB use might be caused by specific GPs
and related to a greater reliance on drug company
information or susceptibility to follow the specialists’
lead in the use of new drugs, as suggested previously
[31].
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Appendix
The ICPC codes [22] and ATC codes [23] shown in
the following table were used to assess presence of
(co)morbidity.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ICPC codes ATC codes
Angina pectoris K74
Ankle oedema K09





Hypercholesterolemia T93 B04, C10
Hypertension K85, K86, K87
Myocardial infarction K75, K76
Proteinuria/renal insufficiency U98.1, U99.1
Stroke K89, K90
COPD, chronic obstructive pulmonary disease; ICPC, International Classification
for Primary Care; ATC, anatomical therapeutical chemical classification.
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